IBI3022 / Innovent Biologics - LARVOL DELTA

Topic: Trop2 and B7H4 bi-specific ADC with improved efficacy and safety for gynecologic cancers (PRNewswire) - "Innovent Biologics...announces that preclinical data...from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025....In vitro studies demonstrate that IBI3022 exhibits superior cytotoxicity in HT29 cells overexpressing Trop2 and B7H4 compared to mono-specific ADC benchmarks targeting Trop2 or B7H4. In vivo, IBI3022 demonstrates enhanced tumor suppression compared to mono-specific ADC benchmarks in various tumor models with differing levels of Trop2 and B7H4 expression."

Preclinical • Solid Tumor

Trop2 and B7H4 bi-specific ADC with improved efficacy and safety for gynecologic cancers (AACR 2025) - "Additionally, IBI3022 shows comparable efficacy to B7H4 ADC in B7H4-positive HCC1569 cells and to Trop2 ADC IBI130 in Trop2-positive BxPC3 and HCC1954 cells. The developability profile of IBI3022 is favorable, and notably, it is well-tolerated in cynomolgus macaques at doses up to 50 mg/kg. Overall, IBI3022 represents a promising bi-specific ADC for the treatment of gynecologic cancers, offering improved efficacy and safety profiles."

Clinical • Breast Cancer • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • TACSTD2 • VTCN1